1. Caudarella R, Vescini F, Rizzoli E, Francucci CM: Salt intake,
hypertension, and osteoporosis. J Endocrinol Invest 2009; 32: 15-20
2. Resnick LM, Laragh JH, Sealey JE, Alderman MH: Divalent
cations in essential hypertension: Relations between serum ionized
calcium, magnesium, and plasma renin activity. N Engl J Med 1983;
309: 888-891
3. Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB: Unravelling
the links between calcium excretion, salt intake, hypertension,
kidney stones and bone metabolism. J Nephrol 2000; 13: 169-177
4. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA: High blood
pressure and bone-mineral loss in elderly white women: A
prospective study. Study of Osteoporotic Fractures Research Group.
Lancet 1999; 354: 971-975
5. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR: Use of betablockers
and risk of fractures. JAMA 2004; 292: 1326-1332
6. Rejnmark L, Vestergaard P, Mosekilde L: Treatment with betablockers,
ACE inhibitors, and calcium-channel blockers is
associated with a reduced fracture risk: A nationwide case-control
study. J Hypertens 2006; 24: 581-589
7. Nishiya Y, Sugimoto S: Effects of various antihypertensive drugs on
the function of osteoblast. Biol Pharm Bull 2001; 24(6): 628-633
8. Ritchie CK, Maercklein PB, Fitzpatrick LA: Direct effect of calcium
channel antagonists on osteoclast function: Alterations in bone
resorption and intracellular calcium concentrations. Endocrinology
1994; 135(3): 996-1003
9. Halici Z, Borekci B, Ozdemir Y, Cadirci E, Suleyman H: Protective
effects of amlodipine and lacidipine on ovariectomy-induced bone
loss in rats. Eur J Pharmacol 2008; 579(1-3): 241-245
10. Gradosova I, Zivna H, Palicka V, Hubena S, Svejkovska K,
Zivny P: Protective effect of amlodipine on rat bone tissue after
orchidectomy. Pharmacology 2012; 89 (1-2): 37-43
11. Ruilope LM, Segura J: The importance of integrated risk
management when treating patients with hypertension: Benefi ts
of angiotensin II receptor antagonist therapy. Clin Exp Hypertens
2008; 30: 397-414
12. Broulík PD, Tesar V, Zima T, Jirsa M: Impact of antihypertensive
therapy on the skeleton: Effects of enalapril and AT1 receptor
antagonist losartan in female rats. Physiol Res 2001; 50: 353-358
13. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza
Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R:
Angiotensin II accelerates osteoporosis by activating osteoclasts.
FASEB J 2008; 22: 2465-2475
14. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T,
Nakashima K, Inagami T, Ezura Y, Noda M: Angiotensin II type
2 receptor blockade increases bone mass. J Biol Chem 2009; 284:
4857-4864
15. Li YQ, Ji H, Shen Y, Ding LJ, Zhuang P, Yang YL, Huang QJ:
Chronic treatment with angiotensin AT1 receptor antagonists
reduced serum but not bone TGF-beta1 levels in ovariectomized
rats. Can J Physiol Pharmacol 2009; 87(1): 51-5516. Hiruma Y, Inoue A, Hirose S, Hagiwara H: Angiotensin II stimulates
the proliferation of osteoblast-rich populations of cells from rat
calvariae. Biochem Biophys Res Commun 1997;230:176-178
17. Trouvin AP, Goëb V: Receptor activator of nuclear factor-κB ligand
and osteoprotegerin: Maintaining the balance to prevent bone loss.
Clin Interv Aging 2010; 5: 345-354
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella
EJ; National Heart, Lung, and Blood Institute Joint National
Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure; National High Blood Pressure Education
Program Coordinating Committee: The Seventh Report of the Joint
National Committee on prevention, detection, evaluation, and
treatment of high blood pressure: The JNC 7 report. JAMA 2003;
289: 2560-2572
19. Akatsu T, Takahashi N, Udagawa N, Sato K, Nagata N, Moseley JM,
Martin TJ, Suda T: Parathyroid hormone (PTH)-related protein is a
potent stimulator of osteoclast-like multinucleated cell formation to
the same extent as PTH in mouse marrow cultures. Endocrinology
1989; 125(1): 20-27
20. Ushijima K, Liu Y, Maekawa T, Ishikawa E, Motosugi Y, Ando H,
Tsuruoka S, Fujimura A: Protective effect of amlodipine against
osteoporosis in stroke-prone spontaneously hypertensive rats. Eur
J Pharmacol 2010; 635: 227-230
21. Shimizu H, Nakagami H, Yasumasa N, Mariana OK, Kyutoku M,
Koriyama H, Nakagami F, Shimamura M, Rakugi H, Morishita
R: Cilnidipine, but not amlodipine, ameliorates osteoporosis in
ovariectomized hypertensive rats through inhibition of the N-type
calcium channel. Hypertens Res 2012; 35(1): 77-81
22. Kosaka N, Uchii M: Effect of benidipine hydrochloride, a
dihydropyridine-type calcium antagonist, on the function of mouse
osteoblastic cells. Calcif Tissue Int 1998; 62(6): 554-556
23. Zahanich I, Graf EM, Heubach JF, Hempel U, Boxberger S, Ravens
U: Molecular and functional expression of voltage-operated calcium
channels during osteogenic differentiation of human mesenchymal
stem cells. J Bone Miner Res 2005; 20(9): 1637-1646
24. Manolagas SC: Birth and death of bone cells: Basic regulatory
mechanisms and implications for the pathogenesis and treatment of
osteoporosis. Endocr Rev 2000; 21(2): 115-137
25. Ma L, Ji JL, Ji H, Yu X, Ding LJ, Liu K, Li YQ: Telmisartan
alleviates rosiglitazone-induced bone loss in ovariectomized
spontaneous hypertensive rats. Bone 2010; 47: 5-11
26. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita
S, Nimura Y, Ishida J, Fukamizu A, Ikeda K: Activation of
renin-angiotensin system induces osteoporosis independently of
hypertension. J Bone Miner Res 2009; 24(2): 241-250
27. Kwok T, Leung J, Zhang YF, Bauer D, Ensrud KE, Barrett-Connor
E, Leung PC; Osteoporotic Fractures in Men (MrOS) Research
Group: Does the use of ACE inhibitors or angiotensin receptor
blockers affect bone loss in older men? Osteoporos Int 2012; 23(8):
2159-2167
Thank you for copying data from http://www.arastirmax.com
